CFH and ARMS2 genetic risk determines progression to neovascular age-related macular degeneration after antioxidant and zinc supplementation
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Significance: Age-related macular degeneration (AMD) is the leading cause of severe vision loss in the elderly and has major economic and quality-of-life impact. Prophylactic high-dose zinc and antioxidant supplements treatments are typically recommended with the assumption of homogeneously distributed benefit and risk of developing neovascular AMD. We show that individual variation at complement factor H and age-related maculopathy susceptibility 2 , genes which predispose to AMD, also determines the effectiveness of nutritional prophylaxis. Some individuals paradoxically experience worsening disease with treatment, while others experience greater than average benefit. These divergent responses are difficult to identify when treatment effects have long latency. Understanding individual variations in prophylactic treatment response should inform future research and optimize health outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Age-related macular degeneration
Jager, R. D., Mieler, W. F., & Miller, J. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801537 · Cited by 1,379
Statistical data analysis in the computer age
Efron, B., & Tibshirani, R. (1991) · Science · doi:10.1126/science.253.5018.390 · Cited by 1,192 · cited 1×
“To evaluate the presence of a genetics–treatment interaction, we used the bootstrapping technique (22, 23).”
MethodSelf-citation(2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.11.1484 · Cited by 739
Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration
Seddon, J. M., Francis, P. J., George, S., Schultz, D. W., Rosner, B., & Klein, M. L. (2007) · JAMA · doi:10.1001/jama.297.16.1793 · Cited by 330
Seddon, J. M., Reynolds, R., Yu, Y., Daly, M. J., & Rosner, B. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.04.029 · Cited by 198 · cited 1×
“Genetic factors add to retinal phenotype as predictors of advanced disease (4).”
BackgroundKlein, M. L., Francis, P. J., Rosner, B., Reynolds, R., Hamon, S. C., Schultz, D. W., Ott, J., & Seddon, J. M. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.01.036 · Cited by 172 · cited 1×
“(10) first observed that the benefit of the AREDS formulation was eliminated for subjects with high-risk CFH alleles.”
BackgroundChew, E. Y., Klein, M. L., Clemons, T. E., Agrón, E., Ratnapriya, R., Edwards, A. O., Fritsche, L. G., Swaroop, A., & Abecasis, G. R. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.008 · Cited by 94
Chew, E. Y., Klein, M. L., Clemons, T. E., Agrón, E., & Abecasis, G. R. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.10.012 · Cited by 61
Assel, M. J., Li, F., Wang, Y., Allen, A. S., Baggerly, K. A., & Vickers, A. J. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.09.008 · Cited by 48
Research works printed but not linked: 27
- 10.1186/s40662-016-0063-5 · DOI · Paper page
- 10.1016/j.ajo.2012.04.017 · DOI
- 10.1001/jamaophthalmol.2015.18 · DOI
- 10.1167/iovs.11-8657 · DOI · Paper page
- 10.1016/j.ophtha.2013.01.021 · DOI · Paper page
- 10.1136/bjophthalmol-2016-308624 · DOI · Paper page
- 10.1016/j.ophtha.2014.07.049 · DOI
- 10.1016/j.ophtha.2013.07.039 · DOI
- 10.1214/aos/1176344552 · DOI · Paper page
- 10.1016/j.jtcvs.2006.02.002 · DOI
- 10.1038/nmeth.3414 · DOI · Paper page
- 10.1016/j.ophtha.2014.10.023 · DOI
- A Henning AREDS dbGAP Data Tables: A User’s Guide. Available at https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetPdf.cgi?id=phd001552.1. Accessed November 13 2017. (2009).
- 10.1007/978-1-4899-4541-9 · DOI · Paper page
- 10.1056/NEJMsa0907130 · DOI · Paper page
- 10.1016/j.cccn.2005.04.002 · DOI · Paper page
- 10.1002/sim.5681 · DOI · Paper page
- A Domalpally, , Peripheral retinal changes associated with age-related macular degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 report number 12 by the Age-Related Eye Disease Study 2 Optos PEripheral RetinA (OPERA) study research group. Ophthalmology; Writing Committee for the OPTOS PEripheral RetinA (OPERA) study (Ancillary Study of Age-Related Eye Disease Study 2) 124, 479–487 (2017). · DOI
- 10.1016/j.ophtha.2015.03.005 · DOI
- 10.1016/j.ophtha.2007.06.021 · DOI
- 10.1167/iovs.08-2514 · DOI · Paper page
- 10.1016/j.exer.2006.12.015 · DOI
- 10.1016/j.imbio.2011.10.003 · DOI · Paper page
- 10.1042/BST0380894 · DOI
- 10.1016/j.jmb.2011.03.006 · DOI · Paper page
- 10.1016/j.jmb.2008.10.030 · DOI
- 10.1074/jbc.M114.605691 · DOI
Cited by
Age-Related Macular Degeneration Preferred Practice Pattern®
Flaxel, C. J., Adelman, R. A., Bailey, S. T., Fawzi, A., Lim, J. I., Vemulakonda, G. A., & Ying, G.-S. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.09.024 · Cited by 349
Lutein and Zeaxanthin and Their Roles in Age-Related Macular Degeneration—Neurodegenerative Disease
Mrowicka, M., Mrowicki, J., Kucharska, E., & Majsterek, I. (2022) · Nutrients · doi:10.3390/nu14040827 · Cited by 299
Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update
Lin, F.-L., Wang, P.-Y., Chuang, Y.-F., Wang, J.-H., Wong, V. H. Y., Bui, B. V., & Liu, G.-S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.029 · Cited by 74
Maurya, M., Bora, K., Blomfield, A. K., Pavlovich, M. C., Huang, S., Liu, C.-H., & Chen, J. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.369098 · Cited by 63
“…pathogenesis and disease prevention, although the AREDS formula is not universally recommended by a few other studies with no effects or unanticipated health risks (Evans, 2008; Datta et al., 2017), which potentially reflects the interaction of genetics and vitamin supplement (Vavvas et al., 2018).”
Influentialvan Asten, F., Chiu, C.-Y., Agrón, E., Clemons, T. E., Ratnapriya, R., Swaroop, A., Klein, M. L., Fan, R., & Chew, E. Y. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.06.004 · Cited by 27
Metadata
- Authors
- Vavvas, D. G., Small, K. W., Awh, C. C., Zanke, B. W., Tibshirani, R. J., & Kustra, R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2018-01-08
- Volume
- 115
- Issue
- 4
- Pages
- E696-E704
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2782610741
- Cited by
- 67
- References
- 10
- FWCI
- 7.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CFH and ARMS2 genetic risk determines progression to neovascular age-related macular degeneration after antioxidant and zinc supplementation. https://app.cochat.ai/papers/10.1073/pnas.1718059115
- The paper
- Vavvas, D. G., Small, K. W., Awh, C. C., Zanke, B. W., Tibshirani, R. J., & Kustra, R. (2018). CFH and ARMS2 genetic risk determines progression to neovascular age-related macular degeneration after antioxidant and zinc supplementation. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1718059115
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.